share_log

康希諾生物：海外監管公告

CANSINOBIO: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 13 10:43
Summary by Moomoo AI
康希諾生物（股份代號：6185）於2024年3月13日發布海外監管公告，公告指出公司近日收到巴西法院送達的訴訟通知，該訴訟由Belcher Farmaceutica Ltda. 提起，要求康希諾生物賠償約1.67億雷亚尔（約合人民幣2.41億元）。訴訟源於2021年康希諾生物授權Belcher在巴西代表其進行新冠疫苗的註冊和商業化談判，但因條件未滿足，康希諾生物於同年6月撤銷授權。目前，康希諾生物的新冠疫苗尚未在巴西獲得緊急使用許可，也未在巴西進行銷售。康希諾生物表示，已聘請專業律師團隊應訴，並認為公司具有較強的抗辯立場，該訴訟不會對公司日常生產經營產生重大影響。公司將根據案件進展及時履行信息披露義務。
康希諾生物（股份代號：6185）於2024年3月13日發布海外監管公告，公告指出公司近日收到巴西法院送達的訴訟通知，該訴訟由Belcher Farmaceutica Ltda. 提起，要求康希諾生物賠償約1.67億雷亚尔（約合人民幣2.41億元）。訴訟源於2021年康希諾生物授權Belcher在巴西代表其進行新冠疫苗的註冊和商業化談判，但因條件未滿足，康希諾生物於同年6月撤銷授權。目前，康希諾生物的新冠疫苗尚未在巴西獲得緊急使用許可，也未在巴西進行銷售。康希諾生物表示，已聘請專業律師團隊應訴，並認為公司具有較強的抗辯立場，該訴訟不會對公司日常生產經營產生重大影響。公司將根據案件進展及時履行信息披露義務。
Conchino Biologics (stock code: 6185) issued an Overseas Regulatory Notice on March 13, 2024, indicating that the company has recently received a notice of action filed by the Brazilian Court, which is being brought by Belcher Farmaceutica Ltda. It asked for compensation of about 1.67 billion reais (about RMB2.41 million) for Conchino's biological compensation. The lawsuit stems from a 2021 license for Conchino Biologics Belcher in Brazil to conduct registration and commercialization negotiations for the COVID-19 vaccine on its behalf, but due to conditions not being met, Conchino Biologics revoked the license in June of the same year. At present, the coronavirus vaccine from Conchino Bio has not been granted an emergency use permit in Brazil, nor is it sold in Brazil. Consino Bios said...Show More
Conchino Biologics (stock code: 6185) issued an Overseas Regulatory Notice on March 13, 2024, indicating that the company has recently received a notice of action filed by the Brazilian Court, which is being brought by Belcher Farmaceutica Ltda. It asked for compensation of about 1.67 billion reais (about RMB2.41 million) for Conchino's biological compensation. The lawsuit stems from a 2021 license for Conchino Biologics Belcher in Brazil to conduct registration and commercialization negotiations for the COVID-19 vaccine on its behalf, but due to conditions not being met, Conchino Biologics revoked the license in June of the same year. At present, the coronavirus vaccine from Conchino Bio has not been granted an emergency use permit in Brazil, nor is it sold in Brazil. Consino Bios said it had hired a team of professional lawyers to sue and believed the company had a strong defense position that the lawsuit would not have a significant impact on the company's day-to-day production operations. The Company will fulfill its obligation to disclose information in a timely manner based on the progress of the case.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more